Assessing Renal Dysfunction Incidence Related to Intravenous Acyclovir Usage Authors: Marwa Said Aljahwari, Mohammad Abobakr Alghazali, Aya Said Alsaidi Published: 2026 ABSTRACT SummaryObjectives:This study aimed to assess the incidence and contributing factors of renal dysfunction among patients receiving intravenous (IV) acyclovir at Khoula Hospital, Muscat, Oman. Specifically, this study aimed to evaluate the incidence of acute kidney injury (AKI) following IV acyclovir administration, associated risk factors and potential preventive strategies to reduce nephrotoxicity.Methods:This retrospective cohort study was conducted at Khoula Hospital and included patients aged 12–80 years who received IV acyclovir between January 2019 and December 2023. Patients with pre-existing renal disease or increased baseline serum creatinine were excluded. The sample size was computed using Daniel's formula, resulting in a minimum sample size of 92 patients.Results:A total of 99 patients were included; 64.6% were males and 35.4% females. The incidence of AKI was 34.3% (n = 34, 95% confidence interval [CI]: 24.9–43.7). Dose reduction was required in 29.3% of AKI cases, and hydration with slow infusion was applied to all patients. Significant associations were observed with nationality, where non-Omani patients had a higher incidence of AKI compared to Omanis (66.7% versus 27.2%, odds ratio = 5.46, 95% CI: 1.79–16.04; P = 0.001). AKI incidence increased with the number of concomitant nephrotoxic medications (P = 0.004).Conclusion:Nationality and concomitant nephrotoxic medications were significantly associated with AKI risk in patients receiving IV acyclovir. Non-Omani patients on multiple nephrotoxic agents demonstrated higher susceptibility to AKI. Advances in Knowledge This study reports the incidence of acute kidney injury among patients receiving intravenous (IV) acyclovir in a tertiary hospital in Oman. This study reports the incidence of acute kidney injury among patients receiving intravenous (IV) acyclovir in a tertiary hospital in Oman. It reveals nationality as a significant factor associated with acyclovir-related acute kidney injury (AKI), an aspect not well documented in previous regional studies. It reveals nationality as a significant factor associated with acyclovir-related acute kidney injury (AKI), an aspect not well documented in previous regional studies. A significant association between AKI and the use of multiple concomitant nephrotoxic medications is reported. A significant association between AKI and the use of multiple concomitant nephrotoxic medications is reported. These findings contribute locally relevant data that promote understanding of acyclovir-associated renal toxicity in routine clinical practice. These findings contribute locally relevant data that promote understanding of acyclovir-associated renal toxicity in routine clinical practice. Application to Patient Care Patients prescribed IV acyclovir should undergo careful assessment of AKI risk before initiation of treatment. Patients prescribed IV acyclovir should undergo careful assessment of AKI risk before initiation of treatment. Avoidance or minimisation of concomitant nephrotoxic medications may reduce the risk of acyclovir-associated AKI. Avoidance or minimisation of concomitant nephrotoxic medications may reduce the risk of acyclovir-associated AKI. Close monitoring of renal function and appropriate dose adjustment are essential, specifically in patients at higher risk. Close monitoring of renal function and appropriate dose adjustment are essential, specifically in patients at higher risk. Implementation of preventive measures, including adequate hydration and slow infusion rates, should be encouraged in clinical practice. Implementation of preventive measures, including adequate hydration and slow infusion rates, should be encouraged in clinical practice. 1. Introduction Acyclovir is a nucleoside analogue antiviral widely used in the treatment of herpesvirus infections, primarily herpes simplex virus (HSV) and varicella-zoster virus (VZV).[1] Its selective activation by viral thymidine kinase allows conversion into acyclovir triphosphate, an active metabolite that competitively inhibits viral DNA polymerase and terminates viral DNA synthesis.[23] This selectivity contributes to acyclovir's favourable safety profile and makes it an essential therapeutic option in both outpatient and inpatient settings.[3] Intravenous (IV) acyclovir, specifically, is the preferred formulation for severe HSV and VZV infections due to its rapid systemic bioavailability and its capacity to achieve therapeutic plasma concentrations within 1–2 hours of administration.[45] In spite of its clinical benefits, IV acyclovir is mainly eliminated unchanged by the kidneys, with up to 90% excreted in the urine.[678910] This high dependence on renal clearance rises vulnerability to nephrotoxicity, especially when high doses, rapid infusion rates or inadequate hydration are implicated.[6] Acyclovir-associated AKI reflects a significant clinical issue as renal dysfunction may prolong hospitalisation, defer antiviral therapy, increase healthcare costs and rise patient morbidity.[1112] Previous studies have reported multiple risk factors, comprising advanced age, dehydration, pre-existing renal impairment, concomitant use of nephrotoxic medications and inappropriate dosing or methods of infusion.[1314] Several real-world studies have evaluated the incidence and risk factors of acyclovir-associated nephrotoxicity in hospitalised patients, reporting variable rates of AKI depending on patient characteristics, dosing practices and clinical settings. For example, retrospective analyses have demonstrated that factors such as diabetes and high daily doses of acyclovir may influence the risk of nephrotoxicity in clinical practice.[4] In addition, a retrospective study reported that obesity was an independent predictor of acyclovir-induced nephrotoxicity, with an incidence of approximately 21% among treated patients.[9] Nevertheless, results throughout studies are inconsistent, with differences in study design, patient populations and clinical practices leading to the observed variance. These inconsistencies emphasise the necessity for establishing locally relevant risk profiles, particularly in hospitals where IV acyclovir is routinely used for treating serious viral infections.[1115] Although acyclovir's extensive use, local evidence on the incidence and predictors of renal dysfunction following IV acyclovir administration in Oman remains limited, with only one prior single-centre study conducted at Sultan Qaboos University Hospital in Muscat, Oman. That study evaluated hospitalised patients between January 2016 and December 2020 using the kidney disease Improving Global Outcomes (KDIGO) criteria. In contrast, the current study was conducted at Khoula Hospital in Muscat between January 2019 and December 2023 providing more recent data a different patient cohort, contributing to the existing evidence on acyclovir-associated renal dysfunction in Oman.[6] Most of the available research arises from a global context, where demographic characteristics, comorbidity patterns and clinical protocols vary markedly from those in Oman.[1016] Bridging this gap is crucial for enhancing patient safety and optimising antiviral therapy. Moreover, determining adjustable factors may help healthcare providers to implement preventive practices that mitigate the probability of acyclovir-induced nephrotoxicity and enhance overall treatment outcomes.[1718] Therefore, this study aimed to determine the incidence of acyclovir-associated renal dysfunction and to identify its predictors among hospitalised patients receiving IV acyclovir at a tertiary care hospital in Oman. By addressing these objectives, the study contributes to improving patient care, reducing renal complications and informing future clinical protocols for the safe and effective use of IV acyclovir. 2. Methods This retrospective cohort study was performed at Khoula Hospital, one of the major tertiary care institutions in Oman, well-known for its specialised surgical, medical and trauma services. All hospitalised patients who received IV acyclovir between January 2019 and December 2023 were included. IV acyclovir was prescribed for indications including meningoencephalitis, encephalitis, meningitis and other suspected severe herpes virus infections. Dosing was determined by the treating physician based on the clinical indication and adjusted according to renal function. Acyclovir was administered as a slow IV infusion over 1–2 hours. Patients typically received IV hydration with normal saline as a continuous infusion at approximately 125 mL/hour for 1 hour prior to acyclovir administration, which was continued for up to 6 hours after the last dose. Renal function tests were monitored daily or on alternate days at the discretion of the treating team, while urine output was not routinely recorded. Details of institutional practices compared with recommended protocols are presented in Table 1. Table 1.Khoula hospital protocols and recommended protocols for the administration of intravenous acyclovir to prevent acute kidney injury[4183132].Khoula Hospital protocolRecommended protocolInfusionSlow IV drug infusion over 1–2 hoursSlow IV drug infusion over 2 hoursHydration1 hour hydration with NS (125 mL/hour) and continue for 6 hours after the last dose of acyclovirMaintain adequate hydration with a minimum of 2 litres of fluids per dayRFTDaily or alternative day RFTDaily RFTUrine outputNot routineMaintain urine output of at least 50 mL/hourIV = intravenous; NS = normal saline; RFT = renal function test. Khoula hospital protocols and recommended protocols for the administration of intravenous acyclovir to prevent acute kidney injury[4183132]. IV = intravenous; NS = normal saline; RFT = renal function test. The study population included all inpatients aged 12 to 80 years who were administered at least 1 dose of IV acyclovir during their hospital stay. Patients aged ≥12 years were included because, according to institutional practice at Khoula Hospital, adolescents in this age group received IV acyclovir dosing and renal monitoring protocols similar to adults. Therefore, they were analysed as part of a single cohort rather than as a separate subgroup. The number of patients aged 12–18 years was limited (n = 11), precluding meaningful subgroup analysis. Only patients with documented serum creatinine measurements both before starting IV acyclovir and after its administration were eligible for inclusion, to guarantee that renal outcomes could be accurately attributed to acyclovir exposure. Patients with AKI at baseline were excluded. Baseline AKI was defined according to KDIGO criteria as an increase in serum creatinine ≥0.3 mg/dL within 48 hours or ≥1.5 times the baseline value. Baseline renal function was determined using the most recent serum creatinine measurement within 3 months prior to admission. Patients with pre-existing chronic kidney disease were also excluded and were identified based on a documented diagnosis or an estimated glomerular filtration rate <60 mL/min/1.73 m2 for at least 3 months prior to admission. Baseline renal function was assessed using a single serum creatinine value obtained immediately prior to initiation of IV rather than averaging multiple values or categorising patients based on laboratory reference ranges. Estimation of creatinine clearance or glomerular filtration rate were not performed as the variables required for their accurate calculation were not consistently available in this retrospective study. An estimated 145 hospitalised patients received IV acyclovir during the study period. The required sample size was determined using Daniel's formula for prevalence studies, based on an anticipated AKI incidence of 20.1%, derived from a previously published single-centre Omani study:[6] n=z2.p(1-p)d2 Where n is the required sample size; Z is 1.96 (z-score for 95% confidence); p is 0.201 (expected prevalence); and d is 0.05 (precision). As the estimated target population (N = 145) was smaller than the calculated requirement, the finite population correction was applied using the following formula where n is 246 and N is 145: nadj=n1+(n-1N) Thus, the minimum recommended sample size was 92 patients. Data were obtained retrospectively from the AlShifa Hospital Information System, using a structured data collection form developed by the investigators to systematically capture all relevant study variables, included sociodemographic characteristics such as age, sex, nationality, as well as medical history, including presence of hypertension (HTN), diabetes mellitus (DM), smoking status, alcohol consumption and other chronic conditions. Clinical information was also collected, containing the primary diagnosis, indication for acyclovir therapy, baseline renal function and hydration status. Acyclovir treatment details were documented, indication for therapy, comprising dose, frequency, duration, infusion rate and timing of serum creatinine measurements. In addition, concomitant medications used were recorded, with particular attention to nephrotoxic drugs such as nonsteroidal anti-inflammatory drugs (NSAIDs), aminoglycosides, vancomycin, angiotensin converting enzymes inhibitors, angiotensin receptor blockers and diuretics. Renal outcomes were obtained by documenting AKI occurrence based on KDIGO criteria, serial serum creatinine values, management interventions (hydration, dose reduction, medication discontinuation) and time to AKI onset and recovery. AKI was defined according to KDIGO criteria as an increase in serum creatinine by ≥0.3 mg/dL (≥26.5 μmol/L) within 48 hours or ≥1.5 times the baseline value within 7 days. AKI staging was performed based on the magnitude of serum creatinine increase. Baseline serum creatinine was defined as the value obtained within 48 hours prior to initiation of IV acyclovir. Follow-up serum creatinine measurements were obtained daily or on alternate days during therapy. Statistical analyses were performed using Statistical Package for Social Sciences (SPSS) software, Version 29 (IBM Corp., Armonk, New York, USA). Descriptive statistics were used to characterise the study population. Categorical variables were presented as frequencies and percentages while continuous variables were expressed as means with standard deviations and medians, as appropriate. The incidence of AKI was calculated as a proportion of affected patients, accompanied by 95% confidence intervals (CIs). Associations between categorical variables and AKI occurrence were tested using the Chi-square test or Fisher's exact test when cell counts were small. To identify independent predictors of AKI, variables with P <0.25 in univariate analysis were entered into a multivariate logistic regression model. A P-value of <0.05 was considered statistically significant. 3. Results A total of 99 patients were included in this study; of the 145 identified patients, 46 were excluded due to incomplete data, loss to follow-up or failure to meet eligibility criteria [Fig. 1]. In the included cohort, 64.6% (n = 64) were males and 35.4% (n = 35) were females, resulting in a male-to-female ratio of approximately 1.8:1. Although gender was not statistically significant, there was a trend toward higher AKI rates among females compared to males (45.7% versus 28.1%; P = 0.078) [Table 2]. Flowchart showing patient selection and exclusion for the current study. IV = intravenous. Table 2.Association between baseline demographic characteristics and acute kidney injury among patients receiving intravenous acyclovir (N = 99).n (%) AKI incidence FactorsNoYesChi-squareP value Age in years 1.540.462* <30 (n = 30)17 (56.7)13 (43.3) 30–49 (n = 46)32 (69.6)14 (30.4) ≥50 (n = 23)16 (69.6)7 (30.4) Gender 3.1040.078* Male (n = 64)46 (71.9)18 (28.1) Female (n = 35)19 (54.3)16 (45.7) Nationality 11.0860.006† Omani (n = 81)59 (72.8)22 (27.2) Bengali (n = 6)2 (33.3)4 (66.7) Indian (n = 6)3 (50.0)3 (50.0) Others (n = 6)1 (16.7)5 (83.3) Nationality (Omani vs non-Omani) 10.1940.001* Omani (n = 81)59 (72.8)22 (27.2) Non-Omani (n = 18)6 (33.3)12 (66.7) Smoking/alcohol consumption 0.0011.0† Non-smoker/no alcohol consumption (n = 96)63 (65.6)33 (34.4) Smoker/alcohol consumption (n = 3)2 (66.7)1 (33.3)AKI = acute kidney injury.;*Using the Chi-square test.;†Using Fisher's exact test. Association between baseline demographic characteristics and acute kidney injury among patients receiving intravenous acyclovir (N = 99). AKI = acute kidney injury.; Using the Chi-square test.; Using Fisher's exact test. In terms of nationality, the majority of patients were Omani nationals (81.8%, n = 81). Among the non-Omani group, Bengali and Indian patients represented the largest subgroups, each accounting for 6.1% (n = 6) of the sample. Nationality emerged as a significant factor associated with AKI. The incidence of AKI among non-Omani patients was 66.7%, which was substantially higher compared to 27.2% among Omani patients. This difference was statistically significant (P = 0.001) and corresponded to an odds ratio (OR) of 5.46 (95% CI: 1.79–16.04) [Table 2]. Lifestyle risk factors were largely uncommon in this cohort. Nearly all patients (97%, n = 96) reported no history of smoking or alcohol consumption. The mean age of the study population was 38.4 ± 14.9 years with a median age of 37 years and an overall age range of 12–76 years. When stratified into age groups, most patients were between 30–49 years (46.5%, n = 46), followed by those younger than 30 years (30.3%, n = 30) and patients aged 50 years or older (23.2%, n = 23). Those in early and middle adulthood were most commonly affected by conditions requiring IV acyclovir therapy at Khoula Hospital. Age, despite being a known risk factor for drug-induced nephrotoxicity, did not show a statistically significant association with AKI in this study. The mean baseline serum creatinine of the study population was 74.9 ± 21.9 μmol/L, with a median of 72.1 μmol/L and a range of 30.3–163.6 μmol/L. The results found that out of the 99 patients included in the study, 34.3% (n = 34, 95% CI: 24.9–43.7) developed AKI following IV acyclovir administration. Almost half of the participants (47.5%, n = 47) had at least one chronic medical condition; HTN and DM were the most frequently reported comorbidities, occurring in 16.2% (n = 16) of patients each. Furthermore, 8.1% (n = 8) of the total sample had both HTN and DM. The comorbid conditions, such as HTN and DM, were not significantly associated with AKI occurrence. Interestingly, DM appeared less common among patients who developed AKI, though this was not statistically significant [Table 3]. Table 3.Association between comorbidities and acute kidney injury among patients receiving intravenous acyclovir (N = 99).n (%) AKI incidence FactorsNoYesChi-squareP value Comorbidities 3.0810.079* No (n = 52)30 (57.7)22 (42.3) Yes (n = 47)35 (74.5)12 (25.5) HTN 0.0810.776* No (n = 83)54 (65.1)29 (34.9) Yes (n = 16)11 (68.8)5 (31.3) DM 4.0380.044* No (n = 83)51 (61.4)32 (38.6) Yes (n = 16)14 (87.5)2 (12.5) HTN with DM 0.3370.711† No (n = 91)59 (64.8)32 (35.2) Yes (n = 8)6 (75.0)2 (25.0) Number of comorbidities 4.4650.107* No PMH (n = 52)30 (57.7)22 (42.3) Single PMH (n = 20)13 (65.0)7 (35.0) Two or more PMH (n = 27)22 (81.5)5 (18.5) Admission diagnosis 1.8280.609* Meningoencephalitis (n = 15)9 (60.0)6 (40.0) Encephalitis (n = 38)23 (60.5)15 (39.5) Meningitis (n = 32)22 (68.8)10 (31.3) Others (e.g., herpes, encephalomyelitis, oral ulcers; n = 14)11 (78.6)3 (21.4)AKI = acute kidney injury;HTN = hypertension; DM = diabetes mellitus;PMH = past medical history.*Using the Chi-square test.;†Using Fisher's exact test. Association between comorbidities and acute kidney injury among patients receiving intravenous acyclovir (N = 99). AKI = acute kidney injury; HTN = hypertension; DM = diabetes mellitus; PMH = past medical history. Using the Chi-square test.; Using Fisher's exact test. Among patients who developed AKI, 29.3% (n = 10) required a dose reduction of acyclovir as part of their management plan. Importantly, all patients with AKI (100%) received hydration therapy combined with slow infusion rates. A clear dose–response relationship was observed as the incidence of AKI with no use of nephrotoxic medications was 25.0%; with the use of 1 nephrotoxic medication, the incidence of AKI was 29.0%; and the use of ≥2 nephrotoxic medications resulted in a 60.0% incidence of AKI. This graded increase was statistically significant (P = 0.004). Furthermore, no significant associations were identified between AKI and variables such as duration of acyclovir treatment, total daily dose or admission diagnosis [Table 4,Fig. 2]. Distribution of acute kidney injury according to the number of concomitant nephrotoxic medications. AKI = acute kidney injury. Table 4.Crude association results between acute kidney injury incidence and concomitant medications (N = 99).n (%) AKI incidence FactorsNoYesChi-squareP value Total daily dose of acyclovir 0.0330.857* <2250 mg (n = 28)18 (64.3)10 (35.7) ≥2250 mg (n = 71)47 (66.2)24 (33.8) Treatment duration of acyclovir in days 0.2180.897* <7 (n = 23)16 (69.6)7 (30.4) 7–10 (n = 50)32 (64.0)18 (36.0) >10 (n = 26)17 (65.4)9 (34.6) ACEI/ARB 0.5290.537† No (n = 87)56 (64.4)31 (35.6) Yes (n = 12)9 (75.0)3 (25.0) Vancomycin 3.140.077* No (n = 72)51 (70.8)21 (29.2) Yes (n = 27)14 (51.9)13 (48.1) NSAID 2.0750.150* No (n = 62)44 (71.0)18 (29.0) Yes (n = 37)21 (56.8)16 (43.2) Concomitant nephrotoxic medications 7.510.023* No concomitant drug (n = 32)24 (75.0)8 (25.0) Single drug (n = 47)33 (70.2)14 (29.8) Two or more drugs (n = 20)8 (40.0)12 (60.0) AKI = acute kidney injury; ACEI = angiotensin-converting enzyme inhibitor;ARB = angiotensin II receptor blocker;NSAID = non-steroidal anti-inflammatory drug.*Using the Chi-square test.;†Using Fisher's exact test. Crude association results between acute kidney injury incidence and concomitant medications (N = 99). AKI = acute kidney injury; ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker; NSAID = non-steroidal anti-inflammatory drug. Using the Chi-square test.; Using Fisher's exact test. On multivariate logistic regression analysis, non-Omani nationality (adjusted OR = 6.88, 95% CI: 1.96–24.20; P = 0.003) and the use of 2 or more concomitant nephrotoxic medications (adjusted OR = 5.41, 95% CI: 1.41–20.87; P = 0.014) remained independently associated with AKI. 4. Discussion The primary outcome of this study was that 34.3% of patients receiving IV acyclovir developed AKI during their hospital stay, highlighting a considerable clinical concern. This indicates that approximately 1 in 3 patients experienced some degree of renal dysfunction attributable to acyclovir exposure. The observed incidence falls within the range reported in previous regional and international studies, highlighting the significance of acyclovir-associated nephrotoxicity within this population.[61920] This study also identified two significant predictors of AKI: (1) non-Omani nationality and (2) the number of concomitant nephrotoxic medications. The incidence of AKI in this study aligns with existing literature describing acyclovir nephrotoxicity as a frequent complication in clinical settings were hydration status, comorbidities or concurrent medications may amplify renal risk. While some studies report AKI rates ranging from 10–20%, others demonstrate higher incidences depending on patient-specific and treatment-related factors.[461318] Several factors may explain the relatively high prevalence of AKI observed in the current study. First, the concurrent use of nephrotoxic medications was common and showed a clear dose–response relationship with AKI, with patients receiving 2 or more nephrotoxic agents demonstrating the highest risk. Second, although hydration and slow infusion practices were documented, these measures were not implemented through a fully standardised protocol and may therefore have varied in timing, intensity and consistency across patients. Third, renal function monitoring was performed daily or on alternate days according to clinical practice, which may have influenced the timing of AKI detection. In addition, differences in patients’ characteristics, severity of illness and institutional practice patterns may also account for variation in AKI incidence when compared with previous regional and international studies. Acyclovir-induced nephrotoxicity is most commonly attributed to crystal nephropathy, which occurs when acyclovir precipitates within the renal tubules once urinary solubility thresholds are exceeded.[89] This process may lead to tubular obstruction, local inflammatory responses and reduced glomerular filtration, ultimately resulting in AKI. Clinically, nephrotoxicity can range from mild elevations in serum creatinine to more severe renal impairment, and the onset is often rapid, typically developing within 24–48 hours after initiation of IV acyclovir therapy. These mechanisms highlight the importance of appropriate hydration, controlled infusion rates and close monitoring of renal function during treatment.[910] This observation, specifically the lack of a statistically significant association between acyclovir dose and AKI in the current study, is consistent with findings reported in some studies, which investigated the exposure–safety relationship of acyclovir in a neonatal population and reported no significant association between acyclovir dose and renal impairment within that population.[19] These previous findings may not be directly generalisable to the current study population due to differences in age and clinical characteristics; however, their study indicated that age alone may not necessarily influence the risk of AKI if dosing is appropriate and renal function is closely monitored. Similarly, some pharmacokinetic studies suggest that acyclovir clearance is largely determined by renal function rather than age itself, which may explain the lack of association observed in the present study in terms of age.[118] However, contrary evidence also exists; Xu L et al. reported that older adults receiving IV acyclovir were at increased risk of AKI, particularly those aged 75 and above.[5] Likewise, Al-Alawi et al., found age to be an independent risk factor for acyclovir-induced nephrotoxicity, with the risk increasing incrementally with each additional year of age (OR = 1.04 per year). These findings suggest that age may contribute to AKI risk in specific contexts, especially among individuals with pre-existing renal impairment or comorbidities.[6] The discrepancy between the current results and those of previous studies may be attributed to differences in population characteristics. In the current study, a substantial proportion of patients were relatively young (mean age = 38.4 years) and patients with baseline renal impairment were excluded.[421] Although the study population was relatively young, the incidence of AKI remained high. This may be explained by the significant contribution of medication-related factors, particularly the use of multiple concomitant nephrotoxic agents, which demonstrated a clear dose–response relationship with AKI risk. These findings suggest that, in this cohort, treatment-related exposures rather than age were the predominant determinants of renal injury. A key finding of the current study was the significant association between nationality and the incidence of AKI. Non-Omani patients exhibited a markedly higher AKI rate compared to Omani patients. While no previous studies have specifically examined nationality as a determinant of acyclovir-induced nephrotoxicity in Oman, evidence from the broader nephrology literature supports the idea that gender, ethnicity, and socioeconomic background may influence AKI risk.[22] Hassan et al., reported significant racial disparities in AKI incidence, highlighting that Black patients had up to 30% higher risk of developing AKI compared to White patients, even after adjusting for demographics and clinical factors.[7] It is also possible that some expatriate groups may present to the hospital later in the course of illness, thereby increasing susceptibility to drug-related complications. While further research is needed to clarify these associations, the current findings underscore the importance of recognising nationality as a potential surrogate marker for broader social and biological risk factors. However, this finding should be interpreted with caution. Nationality is unlikely to represent a biological determinant of acyclovir nephrotoxicity and may instead reflect unmeasured confounding factors such as differences in disease severity at presentation, hydration status, access to care or other socioeconomic variables. Therefore, this variable should be considered a surrogate marker rather than a causal risk factor. The current study also found a strong and statistically significant relationship between the number of nephrotoxic medications and the incidence of AKI. Patients receiving no nephrotoxic drugs had a 25% AKI rate, those receiving one drug had a 29% rate and those receiving two or more nephrotoxic drugs experienced a markedly higher rate of 60% (P = 0.004).[617] These findings strongly indicate that cumulative nephrotoxic burden amplifies the renal risk associated with acyclovir, consistent with known synergistic nephrotoxic effects of drugs such as NSAIDs, vancomycin, diuretics and renin–angiotensin system inhibitors. These findings align with the work of Kletzmayer et al., who observed that infants receiving multiple nephrotoxic medications in addition to acyclovir had a significantly higher likelihood of developing AKI.[15] Similarly, in a retrospective clinical study of 287 patients receiving IV acyclovir, Lee et al. demonstrated that concomitant exposure to nephrotoxic medications was an independent predictor of AKI. In multivariate analysis, NSAID use was associated with a 2.63-fold increase in the odds of AKI, while vancomycin use was associated with a 4.35-fold increase in the odd.[23] Importantly, this represents a modifiable risk factor, reinforcing the clinical importance of minimising concurrent nephrotoxic exposure whenever feasible. Although hydration and slow infusion practices were implemented in the current study, the incidence of AKI remained high. This may reflect variability in the timing and consistency of these interventions, as hydration was administered at the discretion of the treating team rather than through a standardised protocol. In addition, renal function monitoring was performed daily or on alternate days, which may have delayed early detection of rising creatinine in some cases. Evidence-based guidelines emphasise that slow IV infusion over at least 2 hours reduces the risk of intratubular acyclovir crystal precipitation and adequate hydration (≥2 litres per day) is required to maintain urine flow; in addition, daily renal function testing to detect early increases in serum creatinine, as well as maintaining urine output ≥50 mL/hour are indicators of adequate renal perfusion.[618] Based on the current study's results, which are consistent with other studies, clinicians should consider minimising exposure to additional nephrotoxic medications whenever possible, ensuring adequate hydration and adhering to recommended infusion protocols to reduce the likelihood of renal complications.[242526272829] This study was subject to some limitations. First, although patients with pre-existing renal impairment and elevated baseline creatinine were excluded to improve internal validity, this may limit the generalisability of the findings to higher-risk populations, such as elderly patients, critically ill individuals and those with chronic kidney disease, who commonly receive IV acyclovir in routine clinical practice. Second, the observed association between nationality and AKI may be influenced by unmeasured confounding factors and causal inferences cannot be established. Third, the requirement for pre- and post-treatment serum creatinine measurements may have introduced selection bias by excluding patients with incomplete monitoring. Finally, the number of patients in the younger age group (12–18 years) was relatively small, which may have limited the ability to detect age-related differences and thereby reduces the generalisability of findings to this subgroup. 5. Conclusion This study identified a substantial incidence of AKI among patients receiving IV acyclovir, with 34.3% of the cohort developing renal dysfunction during treatment. Multivariate analysis demonstrated that non-Omani nationality and the use of two or more concomitant nephrotoxic medications were independently associated with AKI. These findings highlight the importance of careful patient assessment and close renal monitoring when initiating acyclovir therapy, particularly in individuals with identifiable risk factors. Furthermore, the mere presence of preventive measures may be insufficient without standardised implementation as well as timely monitoring; this reinforces the importance of adhering to recommended infusion protocols, ensuring adequate hydration and reducing exposure to additional nephrotoxic medication to minimise acyclovir-induced nephrotoxicity. Future research should explore the underlying reasons for nationality-related disparities, evaluate the effectiveness of enhanced monitoring protocols and investigate potential strategies to further reduce acyclovir-associated nephrotoxicity in diverse patient populations. Authors’ Contribution Marwa Said Aljahwari: Investigation, Data curation, Writing-Review & Editing. Mohammad Abobakr Alghazali: Supervision, Methodology, Writing-Original Draft, Writing-Review & Editing, Validation. Aya Said Alsaidi: Conceptualization, Data curation. Acknowledgement We would like to acknowledge the National University of Science and Technology, Muscat, Oman, and Khoula Hospital, Muscat, Oman, for the collaborations during the process of this research. Ethics Statement The study received ethical approval from the Ethics and Biosafety Committee, College of Pharmacy, National University of Science and Technology (EBS/PRES0601-COP/MSc/11-03/23-24). Additional approval was obtained from the Health Studies and Research Approval Committee of the Ministry of Health, Oman (MoH/CSR/24/28263). Generative AI Declaration During the preparation of this article, the authors used ChatGPT for the paraphrasing of some of the paragraphs and Quill Bot for the grammar checking of the manuscript. Conflict of Interest The authors declare no conflicts of interest. Funding No funding was received for this study. Data Availability Data are available upon reasonable request from the corresponding author.